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Abstract
C/EBPα plays a key role in specifying myeloid lineage development. HoxA9 is expressed in
myeloid progenitors, with its level diminishing during myeloid maturation, and HOXA9 is
over-expressed in a majority of acute myeloid leukemia cases, including those expressing
NUP98-HOXD13. The objective of this study was to determine whether HoxA9 directly
represses Cebpa gene expression. We find 4-fold increased HoxA9 and 5-fold reduced
Cebpa in marrow common myeloid and LSK progenitors from Vav-NUP98-HOXD13 trans-
genic mice. Conversely, HoxA9 decreases 5-fold while Cebpa increases during granulocytic
differentiation of 32Dcl3 myeloid cells. Activation of exogenous HoxA9-ER in 32Dcl3 cells
reduces Cebpa mRNA even in the presence of cycloheximide, suggesting direct repression.
Cebpa transcription in murine myeloid cells is regulated by a hematopoietic-specific +37 kb
enhancer and by a more widely active +8 kb enhancer. ChIP-Seq analysis of primary mye-
loid progenitor cells expressing exogenous HoxA9 or HoxA9-ER demonstrates that HoxA9
localizes to both the +8 kb and +37 kb Cebpa enhancers. Gel shift analysis demonstrates
HoxA9 binding to three consensus sites in the +8 kb enhancer, but no affinity for the single
near-consensus site present in the +37 kb enhancer. Activity of a Cebpa +8 kb enhancer/
promoter-luciferase reporter in 32Dcl3 or MOLM14 myeloid cells is increased ~2-fold by
mutation of its three HOXA9-binding sites, suggesting that endogenous HoxA9 represses
+8 kb Cebpa enhancer activity. In contrast, mutation of five C/EBPα-binding sites in the +8
kb enhancer reduces activity 3-fold. Finally, expression of a +37 kb enhancer/promoter-
hCD4 transgene reporter is reduced ~2-fold in marrow common myeloid progenitors when
the Vav-NUP98-HOXD13 transgene is introduced. Overall, these data support the conclu-
sion that HoxA9 represses Cebpa expression, at least in part via inhibition of its +8 kb
enhancer, potentially allowing normal myeloid progenitors to maintain immaturity and con-
tributing to the pathogenesis of acute myeloid leukemia associated with increased HOXA9.
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Introduction
Hox proteins are best known to mediate pattern formation during early development, but a
subset serve additional functions in adult tissues. HoxA9 is preferentially expressed in myeloid
progenitors during hematopoiesis, and its level diminishes during normal myeloid maturation
[1–3]. Notably, HOXA9 is over-expressed up to 13-fold in>50% of acute myeloid leukemia
(AML) cases, and its increased expression is associated with poor prognosis [4, 5]. Golub et al
1999 found that of 6,187 genes evaluated, HOXA9 over-expression was most highly correlated
with treatment failure. Andreef et al 2009 evaluated 119 adult AML cases and that found 20%
and 10% long-term survival amongst patients with intermediate or high levels of HOXA9,
respectively, compared with 40% survival amongst patients with low-level HOXA9; in addi-
tion, they noted that patients with low-level HOXA9 mainly had favorable cytogenetics, i.e. t
(15;17), t(8;21), or inv(16). HOXA9 gene expression has been found to be up-regulated in
AML cases as a consequence of gene activation by MLL fusion proteins, NUP98 fusion pro-
teins, CALM-AF10, NPM1c mutation, or decreased EZH2 or ASXL1, each often associated
with intermediate- or high-risk cases [6].
Transduction of myeloid progenitors with HoxA9-ER and Meis1 leads to their rapid out-
growth as IL-3-dependent cell lines in the presence of 4-hydroxytamoxifen (4HT), and subse-
quent inactivation of HoxA9-ER by 4HT withdrawal induces their myeloid differentiation [7,
8]. Myeloid progenitor HoxA9 ChIP-Seq data combined with RNA expression analysis in the
setting of active versus inactive HoxA9-ER indicates that HOXA9 contributes to induction of
genes that favor proliferation and survival (e.g. c-Myb, c-Myc, Cdk6, CyclinD1, Bcl-2) and to
repression of genes that inhibit proliferation (Ink4a/b) or direct differentiation (Cebpa) [7–9].
Consistent with these findings, HOXA9 shRNA-mediated knockdown in AML cells leads to
their reduced survival and to upregulation of myeloid differentiation markers [10].
The C/EBPα basic region-leucine zipper transcription factor is required for formation of
granulocyte-monocyte progenitors (GMP) from common myeloid progenitors (CMP) and is
itself mutated in ~10% of AML cases [11]. In addition to its promoter, the murine Cebpa gene
is regulated by a conserved hematopoietic-specific enhancer located at +37 kb and by a more
widely active enhancer located at +8 kb [12–15]. Herein we present data supporting the con-
clusion that HoxA9 directly binds and inhibits the activity of the Cebpa +8 kb enhancer,
strengthening the idea that HoxA9 impairs myeloid differentiation via repression of Cebpa
gene expression in normal hematopoietic stem and progenitor cells and in poor-risk AML
cases.
Materials and methods
Ethics statement
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol
(M016M66) was approved by the Johns Hopkins University Animal Care and Use Committee.
All efforts were made to minimize suffering. Euthanasia was by carbon dioxide asphyxiation.
Marrow FACS analysis and flow cytometry
C57BL/6 Vav-NUP98-HOXD13 and Cebpa +37 kb Enh/Prom-hCD4 transgenic mice were
previously described [16, 17]. Marrow was obtained by flushing femurs and tibias with phos-
phate-buffered saline. GMP, CMP, and Lin-Sca-1+c-Kit+ (LSK) marrow cells were enumerated,
after red blood cell lysis with ammonium chloride, using biotin-anti-Lineage Cocktail, PerCP--
Cy5.5-streptavidin, APC-anti-c-Kit (2B8), PE-Cy7-anti-Sca-1 (D7, eBioscience), PE-anti-
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CD16/CD32 (FcγR, 2.4G2), and Brilliant Violet 421-anti-CD34 (RAM34). Human CD4 was
detected using FITC-anti-hCD4 (RPA-T4). Antibodies were from Pharmingen unless other-
wise specified. Marrow subsets for RNA analysis were obtained after lineage-depletion, using
biotin-conjugated B220, Gr-1, CD11b, Ter119, and CD3 mouse Lineage Cocktail (BD Phar-
mingen), anti-biotin microbeads, MACS columns (Miltenyi Biotec), and antibody staining via
a FACS Aria II cell sorter (BD Biosciences).
Cell culture and transduction
32Dcl3 murine myeloid cells [15] were cultured in Iscove’s modified Dulbecco medium
(IMDM) with 10% heat-inactivated fetal bovine serum (HI-FBS) and 1 ng/mL murine IL-3
(Peprotech). To induce granulocytic differentiation they were washed twice with phosphate-
buffered saline and placed in IMDM, with 10% HI-FBS and 20 ng/mL human G-CSF
(Amgen). MOLM14 human AML cells were cultured in RPMI with 10% HI-FBS. 293T cells
were cultured in Dulbecco modified Eagle medium with 10% HI-FBS. An EcoR1/SalI segment
was transferred from MIPuro to MIG-Hoxa9-ER [7] to generate MIPuro-Hoxa9-ER. MIPuro
or MIPuro-Hoxa9-ER were packaged into retroviral particles using pkat2ecopac and 293T
cells, as described [12], followed by transduction of 32Dcl3 cells for 48 hrs in the presence of
4 μg/mL Polybrene on 12-well plates coated with 25 mg/mL Retronectin. Pooled transductants
were obtained by further culture in the presence of 2 μg/mL puromycin. An MIPuro-Hox-
a9-ER subclone was then obtained by limiting dilution.
RNA analysis and western blotting
RNA from hematopoietic cells was prepared using NucleoSpin RNA II, with use of RNase-free
DNase (Machery-Nagel). First strand cDNA was prepared using ImProm-II reverse transcrip-
tase (Promega) and oligodT primer at 42˚C for 1 hr. Quantitative PCR was carried out using
5–25 ng of each cDNA using Radiant LoRox SYBR Green supermix (Alkali Scientific). Hoxa9,
Cebpa, and ribosomal subunit mS16 internal control primers were:
HoxA9-F: 5’-AGAAAAACAACCCAGCGAAG,
HoxA9-R: 5’-GGGTTATTGGGATCGATGG,
Cebpa-F: 5’-TGGACAAGAACAGCAACGAG,
Cebpa-R: 5’-TCACTGGTCAACTCCAGCAC,
Mpo-F: 5’-GCTCCGCCCGCATTCCTTGT,
Mpo-R: 5’-TTGAGCTGTGTGGCCAGCCG,
mS16-F: 5’-CTTGGAGGCTTCATCCACAT, and
mS16-R: 5’-ATATTCGGGTCCGTGTGAAG.
Western blotting for HoxA9-ER, using murine ERα antiserum (Santa Cruz Biotechnology),
and for β-actin, using monoclonal antibody AC-15 (Sigma), was carried out as described [12].
Gel shift assay
293T cells were transiently transfected with 6 μg CMV, 3 μg CMV-HoxA9 (kindly provided by
E. Eklund), 3 μg CMV-PBX1a (Addgene), or 6 μg CMV-C/EBPα, or with 3 μg of both
CMV-HoxA9 and CMV-PBX1a, in 100 mm dishes using 15 μL Lipofectamine 2000 (Invitro-
gen). Nuclear extracts were prepared two days later and gel shift assay performed, as described
[13]. Oligonucleotide probes containing 50-GCTA or TCGA overhangs were radio-labeled to
similar specific activity with the use of Klenow enzyme and α-P32-dCTP. Sense strands of the
wild-type (WT) probes used, with binding sites underlined, were as follows:
A9/Pbx consensus: 5’-GCTACACATCAATGATTTACGACAACAGGA,
+37kb Enh A9: 5’-GCTACACATCAGTTATTTATCAGAACAGGA, and
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NE-C/EBP: 5’-TCGAGGCCAGGATGGGGCAATACAACCCG.
Additional oligonucleotides used as competitors were:
A9/Pbx M1: 5’-GCTACACATCAATGCGTTACGACAACAGGA,
A9/Pbx M2: 5’- GCTACACATCAATGATGGACGACAACAGGA,
37 kb Mut: 5’-GTACACATCAGTTATGGATCAGAACAGGA,
8 kb A9 site1 WT: 5’-GCTATCCTTGAGTGATTTACAATTTGCAAA,
8 kb A9 site1 Mut: 5’-GCTATCCTTGAGTGATGGACAATTTGCAAA,
8 kb A9 site2 WT: 5’-GCTATGCAAACATGTTTTATTTGATTCCCG,
8 kb A9 site2 Mut: 5’-GCTATGCAAACATGTTGGATTTGATTCCCG,
8 kb A9 site3 WT: 5’-GCTAATTCCCACTGATTTATAGGGAATAAG,
8 kb A9 site3 Mut: 5’-GCTAATTCCCACTGATGGATAGGGAATAAG,
8 kb A9 site4 WT: 5’-GCTATCCACAGGACAGAGCATTTATCCCAGAAC,
8 kb A9 site4 Mut: 5’-GCTATCCACAGGACAGAGCATGGATCCCAGAAC,
NE-C/EBP Mut: 5’-TCGAGGCCAGGATGGGCCTATACAACCCG,
α1: 5’-GATCTGATTTACAATTTGCAAACATGTTTTA
α2: 5’-GATCGTTTTATTTGATTCCCGAGTTCTGCCG,
α3: 5’-GATCGAGTTCTGCCGGGGCAATTACAGTGAC,
α4: 5’-GATCTGCTCGCTGTTAAGAAATGTGTTTG,
α5: 5’-GATCAAATGTGTTTGCCTCACTGTTTTGC,
α6: 5’-GATCACTGTACGCGAAGGCAATTTGTTCCAAA,
α7: 5’-GATCTGTGACCACATTCCCACTGATTTATAGG, and
α8: 5’-GATCCCACTGATTTATAGGGAATAAGCCCTAC.
Transient transfection
The 514 bp murine Cebpa +8 kb enhancer was synthesized (Blue Heron) and positioned
upstream of the -720/+125 Cebpa promoter and luciferase cDNA to generate reporter plasmid
Cebpa +8 kb Enh/Prom-Luc. Variants of this enhancer with mutations in HoxA9 consensus
site 1 (m1), site 2 (m2), site 3 (m3), or in all three sites (m123), or in C/EBPα consensus sites 4
and 5 (m45), 1, 3, and 7 (m137), or all five of these sites (mx5) were also synthesized and posi-
tioned similarly. Mutation of the HoxA9 sites matched those in the mutant gel shift competi-
tors. Mutation of the C/EBPα sites changed 5’-T(T/G)NNGNAA(T/G) to 5’-T(T/G)
NNCNTA(T/G) in the C/EBPα-binding motif. 5E6 32Dcl3 cells proliferating in IL-3 were
transiently transfected with 5 μg of these luciferase reporter DNAs together with 0.5 μg of
CMV-βGal using DEAE-dextran and subjected to luciferase and β-galactosidase assays two
days later as described [13]. 5E6 MOLM14 cells were transiently transfected similarly with
0.5 μg luciferase reporter DNAs alone, due to their high background β-galactosidase activity.
Statistics
Means and standard deviations (SD) are shown. The Student t test was used for statistical
comparisons.
Results
HoxA9 represses Cebpa gene expression
Withdrawal of 4HT from murine myeloid progenitors transformed with HoxA9-ER led to
~2-fold increased Cebpa mRNA expression at 24 hr and ~3-fold at 48 hr [8]. Pan-hematopoi-
etic expression of the NUP98-HOXD13 (NHD13) myeloid oncoprotein using the Vav pro-
moter in mice leads to myelodysplastic syndrome with 4.5-fold increased marrow HoxA9,
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3.5-fold reduced myeloid CFU-GM colonies, 2-fold reduced LSK stem cells, and 3-fold
reduced Lin-Sca-1-c-Kit+ (LK) progenitors [16, 18–20]. Consistent with these results, we find
3-fold reduced GMP, 2-fold reduced CMP, and 6-fold reduced LSK cells in the marrow of
8–10 wk old Vav-NHD13 mice (Fig 1A), with 3- to 6-fold increased HoxA9 mRNA in these
marrow subsets (Fig 1B, left). In addition, we find 5-fold reduced Cebpa in CMP or LSK cells
with only mild reduction in Runx1 (Fig 1B, center and right), a potential C/EBPα target [13].
Lack of reduced Cebpa in GMP may reflect the higher levels of HoxA9 evident in the CMP and
LSK populations. Conversely, when 32Dcl3 murine myeloid cells are induced to differentiate
by transfer from IL-3 to G-CSF, HoxA9 levels decrease and Cebpa and Mpo levels increase (Fig
1C). These data demonstrate an inverse correlation between HoxA9 and Cebpa in myeloid
stem and progenitor cells.
In an effort to demonstrate direct repression of Cebpa expression by HoxA9, we transduced
32Dcl3 murine myeloid progenitor cells with the MIPuro retroviral vector or with the same
vector expressing HoxA9-ER. Western blot analysis detected HoxA9-ER in several 32Dcl3
subclones amongst twelve screened, from which we chose subclone 4 for study (Fig 2A). Note
that HoxA9-ER and β-actin are detected at their expected molecular weights of 66 kd and 42
kd, respectively. Activation of HoxA9-ER with 4HT led, on average, to ~3-fold reduction of
Cebpa mRNA at 4 hr and to ~2-fold reduction at 8 hr, in three independent experiments, with
no reduction evident in the MIPuro control cells, and this repression of Cebpa mRNA expres-
sion was retained in the presence of cycloheximide (CHX), an inhibitor of ribosomal transla-
tion (Fig 2B). These findings indicate that HoxA9 directly represses Cebpa transcription.
HoxA9 binds the Cebpa +8 kb and +37 kb enhancers
ChIP-Seq data for HA-HoxA9, HA-HoxA9-ER, and HA-Meis1, obtained using anti-HA anti-
body, or for endogenous C/EBPα [7, 21], demonstrates that HoxA9 and C/EBPα interact with
both the +8 kb and +37 kb Cebpa enhancers, whereas Meis1 binds exclusively to the +8 kb
enhancer (Fig 3A). Interaction of C/EBPα with both enhancers is consistent with ChIP-Seq
data obtained using murine GMP [13]. In contrast, Runx1, PU.1, GATA-2, and SCL bind
exclusively within the +37 kb enhancer [13].
HoxA9 binds DNA as a HoxA9:Pbx dimer or as a HoxA9:Pbx:Meis1 trimer [22]. PCR-
mediated site selection identified 5’-ATGATTTACGAC as the optimal HoxA9:Pbx1 binding
site [23]. Within this sequence, TGA is thought to bind Pbx and TTTACGACHoxA9, based on
their co-crystal structure [24]. Analysis of in vivo binding sites identifies 5’-TTTA(T/c)
(G/T/A)(A/g/t) as preferred [25]. Based on these consensus sequences, we identified
potential HoxA9-binding sites within the Cebpa +8 kb and +37 kb enhancers. The +37 kb
enhancer contains the sequence 5’-GTTATTTATCA, which differs from the consensus at the
underlined three positions. Of note, this potential HoxA9-binding site overlaps with 5’-
CAGTTA, which binds c-Myb, and with 5’-TGATAA on the opposite DNA strand, which
binds GATA-2 in gel shift assays [13]. The +8 kb enhancer contains four potential HoxA9-
binding sites (Fig 3B). Site 1, 5’-TGATTTACAA, perfectly matches the consensus. Site 2, 5’-
TGTTTTATTT, has one mismatch in the Pbx half-site. Site 3, 5’-TGATTTATAG, perfectly
matches the consensus. Site 4, 5’-GCATTTATCC, has four mismatches.
293T nuclear extracts, prepared after transfection with empty CMV vector, CMV-HoxA9
(A9), CMV-PBX1a (Pbx1), or both CMV-HoxA9 and CMV-PBX1a, were subject to gel shift
analysis using radio-labelled HoxA9/Pbx (A9/Pbx) consensus or +37 kb enhancer HoxA9 site
probes (Fig 4A). Weak binding to both probes was evident using the empty CMV nuclear
extract, indicative of endogenous protein(s) capable of interacting with each probe. Increased
binding to the consensus probe, but not to the +37 kb enhancer probe, was evident using the
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Fig 1. Reciprocal relation between HoxA9 and Cebpa in hematopoietic progenitors. . A) GMP, CMP, and LSK cells were enumerated in marrow from 8 wk
old wild-type (WT) and Vav-NUP98-HOXD13 (Vav-NHD13) transgenic mice. Representative FACS analysis (left) and relative absolute number of GMP,
CMP, and LSK per hind limbs (right, mean and SD from four mice) are shown. B) Total cellular RNAs from GMP, CMP, and LSK cells from WT or Vav-
NHD13 mice were subjected to quantitative PCR analysis for HoxA9, Cebpa, and Runx1 relative to mS16 ribosomal protein mRNA (mean and SD from three
mice). C) HoxA9, Cebpa, and Mpo mRNA levels were assessed in 32Dcl3 cells in IL-3 or after transfer to G-CSF for 1, 2, or 3 days (G1, G2, or G3; mean and SD
from triplicate analysis in one experiment, with p-values relative to IL-3 level). � p<0.05, �� p<0.01, ��� p<0.001, NS—not significant.
https://doi.org/10.1371/journal.pone.0217604.g001
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A9 or A9+Pbx1 extracts. Binding to the consensus probe was stronger using the A9 compared
with the A9+Pbx1 extract, which may reflect sufficient endogenous Pbx and CMV promoter
competition reducing HoxA9 expression when the two plasmids are co-transfected. The
HoxA9 nuclear extract was then subjected to gel shift analysis using the radio-labelled A9/Pbx
consensus probe in the presence of no competitor, 5- or 25-fold excess of unlabeled WT probe,
or 5- or 25-fold excess of either of two mutant oligonucleotides having 2 bp point mutations in
the consensus HoxA9-binding site (Fig 4B). The WT probe was more effective than the mutant
probes at competing for HoxA9 binding, as shown by decreased signal in the presence of
excess unlabeled WT probe compared to the mutant probes, indicating binding of HoxA9 to
the predicted binding motif.
Finally, the A9/Pbx consensus probe was subject to gel shift assay using the A9 nuclear
extract in the presence of no competitor, 25-fold excess of WT or mutant A9/Pbx consensus
probe, WT or mutant +37 kb enhancer probe, or WT or mutant HoxA9-binding sites 1–4
from the +8 kb enhancer (Fig 4C). Again, WT but not mutant A9/Pbx probe competed effec-
tively (lanes 2, 3). The +37 kb enhancer WT probe was ineffective as a competitor (lane 4),
consistent with the lack of evident binding above background when this probe was radio-
labeled and combined with exogenous HoxA9. +8 kb enhancer WT sites 1, 2, and 3, but not 4,
competed for binding of HoxA9 to the consensus probe (lanes 6, 8, 10, and 12), with mutation
of sites 1, 2, or 3 reducing competition (lanes 7, 9, and 11). Of these four sites, site 1 was the
most effective competitor, followed by site 3, reflecting their fully matching the 5’-TTTA(T/
c)(G/T/A)(A/g/t) consensus. Lack of affinity to site 4 is likely due to its four mismatches
Fig 2. HoxA9-ER directly represses Cebpa gene expression in myeloid cells. A) Total cellular proteins from parental 32Dcl3 cells, pooled 32Dcl3 MIPuro
cells, and twelve 32Dcl3 MIPuro-HoxA9-ER subclones were subjected to Western blotting using anti-rabbit ERα anti-serum, followed by stripping the blot and
reprobing with β-actin antibody. B) Total cellular RNAs from these cells prepared after 0, 4, or 8 hr of culture in IMDM/HI-FBS/IL-3 media alone, with 200
nM 4-hydroxytamoxifen (4HT), with 50 μg/mL cycloheximide (CHX), or with both were subjected to quantitative PCR analysis for Cebpa expression relative
to mS16 mRNA. CHX was added 30 min prior to 4HT when combined (mean and SD from three independent experiments).
https://doi.org/10.1371/journal.pone.0217604.g002
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with this consensus, compared with site 2 which has only one mismatch. The lack of affinity
seen when the +37 kb enhancer site was used as a probe, and its inability to act as competitor
under these conditions, likely reflects its three mismatches from the HoxA9 consensus. Over-
all, these data indicate that HoxA9 binds directly to the +8 kb Cebpa enhancer via three sites
and that its interaction with the +37 kb enhancer evident in myeloid progenitor ChIP-Seq may
reflect indirect contact via one or more bound transcription factors.
C/EBPα binds the Cebpa +8 kb enhancer
Binding motifs for C/EBP, RUNX1, PU.1, and MYB family transcription factors are com-
monly found in the vicinity of HoxA9 binding sites identified via ChIP-Seq in myeloid progen-
itors [7–9]. While RUNX1 and PU.1 interact with the +37 kb Cebpa enhancer, neither
interacts with the +8 kb enhancer [13]. In addition, c-Myb did not bind either enhancer when
assessed by ChIP-Seq using a murine myeloid progenitor cell line [26]. C/EBPα binds two sites
within the Cebpa +37 kb enhancer, and mutation of these sites reduces enhancer activity in
32Dcl3 myeloid cells [13]. In addition, we identified eight sequences within the +8 kb enhancer
that matched or nearly matched the C/EBP-binding consensus (Fig 3B). Gel shift analysis was
conducted using a radio-labeled probe containing a known C/EBPα-binding site in the neu-
trophil elastase (NE) promoter and nuclear extract prepared from 293T cells expressing exoge-
nous C/EBPα, together with no competitor, 25-fold excess of unlabeled WT or mutant NE-C/
EBP probe, or 25-fold excess of unlabeled double-stranded oligonucleotides containing each
of the candidate C/EBPα-binding sites (Fig 5). Strong competition was seen with WT but not
mutant NE-C/EBP. In addition, enhancer sites 1, 4, 5, and 7 competed strongly and site 3 com-
peted modestly with the NE probe for C/EBPα binding. Thus, C/EBPα interacts with five
Cebpa +8 kb enhancer sites in vitro, consistent with its in vivo interaction with the enhancer in
myeloid progenitors.
Endogenous HoxA proteins repress and C/EBP proteins activate the +8 kb
enhancer
Point mutations were introduced into HoxA9-binding sites 1–3, or into each site individually,
within the 514 bp +8 kb Cebpa enhancer, and these variants or the WT enhancer were then
positioned upstream of the -720/+125 bp Cebpa promoter and the luciferase cDNA to generate
reporter constructs. Cebpa +8 kb Enh/Prom-Luc or its mutant variants were transiently trans-
fected into murine 32Dcl3 myeloid cells along with CMV-βGal, followed by assessment of
luciferase activity 48 hr later, normalized to β-galactosidase activity (Fig 6A, left). Mutation of
all three HoxA9 sites increased activity 2.5-fold, on average. Mutation of each site individually
mildly increased reporter activity, but not to a significant degree. These same luciferase con-
structs were also transiently transfected into human MOLM14 AML cells, without CMV-βGal
due to high endogenous β-galactosidase activity. MOLM14 cells express the MLL-AF9 fusion
oncoprotein, an inducer of HOXA9 transcription [10]. Mutation of the three HoxA9-binding
sites again increased reporter activity in this context, 1.8-fold on average, and mutation of each
individual binding site also increased activity, although to a lesser extent (Fig 6A, right). These
data indicate that endogenous HoxA transcription factors repress Cebpa +8 kb enhancer activ-
ity in immature myeloid progenitor or leukemia cells.
Fig 3. Binding of HoxA9 and C/EBPα within the Cebpa locus. A) ChIP-Seq data at the Cebpa locus for exogenous, HA-tagged HoxA9, HoxA9-ER, and Meis1
and for endogenous C/EBPα in HoxA9/Meis1- or HoxA9-ER/Meis1-transformed murine myeloid progenitors is shown [7, 21]. B) The sequence of the murine
(M) Cebpa +8 kb enhancer is aligned with the corresponding human (H) + 9 kb CEBPA enhancer. Positions of sites that match or nearly match the HoxA9 or
C/EBPα consensus-binding motifs are shown, with those underlined found in this report to bind these proteins in electrophoretic mobility shift assay (EMSA).
https://doi.org/10.1371/journal.pone.0217604.g003
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Point mutations were also introduced into C/EBPα-binding sites 1, 3, 4, 5, and 7, into adja-
cent sites 4 and 5, or into sites 1, 3, and, 7 within +8 kb Cebpa enhancer, and these variant
enhancers were positioned upstream of the Cebpa promoter and luciferase cDNA. Cebpa +8
Fig 4. HoxA9 binds three sites within the Cebpa +8 kb enhancer. A) 1 ng of radio-labeled HoxA9 (A9)/Pbx consensus probe or Cebpa +37 kb enhancer
HoxA9-binding site probe was incubated with 10 μg of nuclear extract prepared from 293T cells transfected with empty CMV vector or vectors expressing
HoxA9, Pbx1, or both, followed by non-denaturing polyacrylamide gel electrophoresis (PAGE) and autoradiography. The position of the shifted species is
indicated (�). B) 1 ng of radio-labeled A9/Pbx consensus probe was incubated with HoxA9-expressing nuclear extract alone or in the presence of 5 ng or 25 ng
of unlabeled wild-type (WT) probe or either of two mutant probes (M1, M2), followed by PAGE and autoradiography. The sequences of the HoxA9-binding
motifs within the WT and mutant A9/Pbx probe are shown, with mutant bases underlined. C) 1 ng of radio-labeled A9/Pbx consensus probe was incubated
with HoxA9-expressing nuclear extract alone or in the presence of 25 ng of the indicated competitors, followed by PAGE and autoradiography. The HoxA9
motifs within the Cebpa +8 kb enhancer DNAs are shown, along with the base changes present in the mutant (Mut) competitors.
https://doi.org/10.1371/journal.pone.0217604.g004
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Fig 5. C/EBPα binds five sites within the Cebpa +8 kb enhancer. 1 ng of radio-labeled NE-C/EBP probe, containing a C/EBPα-binding
site, was incubated with 10 μg of nuclear extract prepared from 293T cells transfected with empty CMV vector or with a vector expressing
C/EBPα, alone or with 25 ng of the indicated unlabeled competitor double-stranded DNAs, followed by PAGE and autoradiography. The
position of the shifted species is indicated (�). The sequences of the C/EBP-binding motifs within the competitors are shown with mutant
bases underlined.
https://doi.org/10.1371/journal.pone.0217604.g005
Fig 6. HoxA9 represses and C/EBPα activates the Cebpa +8 kb enhancer in immature myeloid cells. A) 32Dcl3 murine myeloid progenitor or MOLM14
human AML cells were transfected with wild-type (WT) Cebpa +8 kb Enh/Prom-Luc or with mutant variants harboring 2 bp point mutations in
HoxA9-binding sites 1, 2, and 3 (m123), or in sites 1, 2, or 3 alone (m1, m2, m3), together with CMV-βGal as internal control for 32Dcl3 cells. The relative
activity of each reporter is shown, with the activity of the WT reporter set to 1.0 in each experiment (mean and SD from six determinations for 32Dcl3 and nine
for MOLM14). B) 32Dcl3 cells were transfected with WT Cebpa +8 kb Enh/Prom-Luc or with mutant variants harboring 2 bp point mutations in C/EBPα-
binding sites 1, 3, 4, 5, and 7 (mx5), 4 and 5 (m45), or 1, 3, and 7 (m137), with CMV-βGal. The relative activity of each reporter is shown, with the activity of
WT reporter set to 1.0 in each experiment (mean and SD from nine determinations).
https://doi.org/10.1371/journal.pone.0217604.g006
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kb Enh/Prom-Luc or its variants were transiently transfected into murine 32Dcl3 myeloid
cells along with CMV-βGal, followed by assessment of luciferase activity 48 hr later, normal-
ized to β-galactosidase activity (Fig 6B). Mutation of all five C/EBPα-binding sites reduced
reporter activity 3-fold, on average. Mutation of sites 4 and 5 had no effect, while mutation of
sites 1, 3, and 7 reduced activity ~2-fold. These data indicate that endogenous C/EBP proteins
activate the Cebpa +8 kb enhancer in 32Dcl3 myeloid cells.
+37 kb enhancer/promoter activity is reduced in the context of elevated
HoxA9
As the near consensus HoxA9 site in the +37 kb enhancer did not interact with HoxA9 in vitro
and overlaps with motifs that bind GATA-2 and c-Myb, we did not evaluate the effect of its
mutation on +37 kb enhancer activity. However, we did take advantage of transgenic mice har-
boring a +37 kb Cebpa enhancer/promoter-hCD4 reporter that expresses cytoplasmically trun-
cated, plasma membrane hCD4 at high levels in CMP and GMP [17]. These mice were bred to
Vav-NHD13 mice, which have elevated HoxA9 in these marrow subsets. Compared with pro-
genitors from Cebpa +37 kb enhancer/promoter mice, introduction of the NHD13 transgene
reduces hCD4 geometric mean fluorescence intensity (MFI) 2.1-fold, on average, in CMP and
1.4-fold in GMP (Fig 7). These findings, coupled with ChIP-Seq data showing that HoxA9
binds the Cebpa +37 kb enhancer but not its promoter, suggest that HoxA9 also represses
Cebpa transcription via its +37 kb enhancer.
Discussion
C/EBPα is required for normal myeloid development, and reduced C/EBPα expression or
activity is evident in the majority of AML cases [11]. The murine Cebpa gene contains a 455 bp
enhancer located at +37 kb that is highly conserved in the human CEBPA locus and functions
specifically in hematopoietic stem and progenitor cells [12–15]. The +37 kb enhancer is bound
Fig 7. Expression of a Cebpa +37 kb enhancer/promoter transgene is reduced in hematopoietic progenitors with increased HoxA9. A) Representative flow
cytometry showing expression of the Cebpa +37 kb enhancer/promoter (Enh/Prom)-human CD4 (hCD4) transgene after breeding to introduce one Vav-
NUP98-HOXD13 (NHD13) allele. SSC—side scatter. B) The geometric mean fluorescence intensity (MFI) for hCD4 within CMP or GMP expressing the
transgene is shown (mean and SD from three determinations).
https://doi.org/10.1371/journal.pone.0217604.g007
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and activated by RUNX1, C/EBPα, GATA-2, SCL, NR4A1/3, PU.1, additional ETS family
transcription factors, and potentially c-Myb in normal myeloid progenitors and is bound and
potentially repressed by RUNX1-ETO in AML cases [13, 27, 28]. Analysis of H3K4me1 and
H3K27Ac histone marks in murine GMP, CMP, and additional marrow hematopoietic pro-
genitors identified a second potential enhancer located at +8 kb in the Cebpa locus [13]. Simi-
lar analysis of H3K27Ac marks in the human CEBPA locus indicates that the corresponding
+9 kb enhancer is active in myeloid cells and also in all non-myeloid, C/EBPα-expressing tis-
sues examined, i.e. liver, lung, adipose, large and small intestines, skin epithelium, and pla-
centa; moreover, 4C-Seq analysis demonstrates interaction of the +9 kb enhancer with the
CEBPA promoter in both myeloid and non-myeloid cell lines [15]. Our prior analysis of
ChIP-Seq data indicates that C/EBPα, but not RUNX1, PU.1, GATA-2, or SCL, binds the +8
kb enhancer [13]. We now further demonstrate that HoxA9 directly binds the +8 kb Cebpa
enhancer via three binding sites and that HoxA9 also localizes to the +37 kb enhancer, likely
via interaction with other bound transcription factors. We show that increased HoxA9 result-
ing from NHD13 myeloid oncoprotein expression is associated with reduced Cebpa in CMP
and LSK marrow cells, decreased HoxA9 as 32Dcl3 cells differentiate is associated with
increased Cebpa, activation of exogenous HoxA9-ER reduces Cebpa even in the presence of a
ribosomal translation inhibitor, and mutation of the three HoxA9-binding sites in the +8 kb
enhancer increases reporter activity in two myeloid cell lines. Moreover, inactivation of Hox-
A9-ER in myeloid progenitors leads to increased Cebpa mRNA [8]. Together, these data indi-
cate that HoxA9 binds and represses Cebpa +8 kb enhancer activity.
Within hematopoiesis HoxA9 expression is prominent in hematopoietic stem and myeloid
progenitors and diminishes during myeloid maturation [1–3]. Our findings suggest that
reduced HoxA9 is a prerequisite for Cebpa to achieve a level required for granulocytic and
monocytic differentiation. HOXA9 expression is also prominent in>50% of human AML
cases [4–6], where it might contribute to myeloid transformation in part by reducing CEBPA
expression and thereby interfering with myeloid differentiation. In addition, our finding that
C/EBPα plays a role in early B lymphopoiesis suggests that HOXA9 induction by MLL-AF4 or
other MLL fusion oncoproteins in preB ALL cases might also suppress CEBPA expression to
contribute to leukemic transformation [6, 29].
HoxA9 is co-expressed with additional HoxA proteins, in particular HoxA5, HoxA7, and
HoxA10, in immature hematopoietic populations, which likely accounts for the observation
that HoxA9-/- mice manifest only mild pancytopenia [30]. Expression of the corresponding
human HOXA genes are often increased together with HOXA9 in human AMLs [1–6]. As the
HOXA proteins have similar DNA-binding consensus motifs [22–24], the increased activity of
the Cebpa +8 kb enhancer/promoter luciferase reporter seen in 32Dcl3 and MOLM14 cells
upon mutation of the three enhancer HoxA9-binding sites may in part reflect reduced binding
of not only HoxA9 but also additional HoxA proteins. Of note, while Pbx antibody super-
shifted the entire HoxA9 consensus complex formed in gel shift assay with 32Dcl3 nuclear
extract, HoxA9 antibody only shifted ~25% of this complex, indicating the presence of addi-
tional HoxA proteins [31]. Nevertheless, as HOXA9 is most consistently induced in murine
and human AMLs and correlates most highly with poor prognosis [4–6], as absence of HoxA9
prevents transformation by MLL-ENL [32], and as HOXA9 depletion is sufficient to induce
proliferation arrest and apoptosis in AML cell lines and in primary AML cells [10], HOXA9
may be the HOXA transcription factor most critical for normal and malignant myelopoiesis.
In addition to repression by HoxA9, we also provide data indicating that C/EBPα directly
binds and activates the Cebpa +8 kb enhancer via five consensus sites, as mutation of these five
binding sites leads to increased Cebpa +8 kb enhancer/promoter activity in 32Dcl3 cells. C/
EBPα was previously shown to bind and activate the Cebpa promoter and +37 kb enhancer
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[13, 33]. Additional C/EBP proteins may also activate the +8 kb enhancer, although C/EBPα is
the most prominent isoform in immature myeloid cells, including in 32Dcl3 cells where C/
EBPα represents the large majority and C/EBPβ only a minor proportion of gel shift species
evident using the consensus NE-C/EBP probe [34, 35].
Enhancers bound by HoxA9 in myeloid progenitors often harbor C/EBP motifs [7–9], and
HoxA9 and C/EBPα directly interact [21]. Whether this interaction facilitates cooperative DNA-
binding and/or engenders cooperative or cross-inhibitory trans-activation activity at these
enhancers requires future investigation. Notably, within the Cebpa +8 kb enhancer, the three
HoxA9-binding sites are located directly adjacent to C/EBPα-binding sites, raising the possibility
that HoxA9 and C/EBPα compete for binding to this enhancer. Of note, among non-hematopoi-
etic tissues that express C/EBPα, several also express HoxA9, i.e. adipose, small and large intes-
tine, and skin, but not liver, lung, or placenta (https://gtexportal.org), potentially reflecting their
mutual regulation of the Cebpa +8 kb and additional enhancers also in these tissues.
Simultaneous binding of HoxA9 and C/EBPα to the +8 kb enhancer in myeloid progenitors
may generate a primed transcriptional state which is resolved upon decrease in HoxA9 during
myeloid maturation. Consistent with this idea, the enhancer is strongly marked by H3K4me1
but only very weakly by H3K27Ac and not at all by H3K27me3 in HoxA9/Meis1-immortalized
myeloid progenitors (S1 Fig). A primed pattern is also evident at the +8 kb enhancer in GMP,
with the activating H3K27Ac histone mark increased substantially in granulocytes [13], poten-
tially reflecting absence of HoxA9 at this terminal stage of myeloid differentiation.
Finally, our finding that a Cebpa +37 kb enhancer/promoter-human CD4 transgene has
reduced activity in CMP and GMP when HoxA9 levels are elevated by a Vav-NHD13 trans-
gene supports the possibility that interaction of HoxA9 with the +37 kb enhancer may also
contribute to repression of Cebpa gene expression during early hematopoiesis or myeloid
transformation.
Supporting information
S1 Fig. The Cebpa +8 kb enhancer is primed in HoxA9/Meis1-immortalized myeloid pro-
genitors. ChIP-Seq data for C/EBPα, HoxA9, H3K27me3, H3K27Ac, and H3K4me1 at the
murine Cebpa locus [9, 21].
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